Morusin

Morusin is a prenylated flavonoid derived from the root bark of Morus alba (white mulberry) that exerts its primary biological effects through inhibition of the NF-κB signaling pathway and induction of mitochondria-dependent apoptosis. Current research is limited to preclinical and in vitro models, with no established human clinical trials confirming its efficacy or safe dosing range.

Origin & History

Morusin is a prenylated flavonoid primarily extracted from the root bark of mulberry trees (Morus alba and related species) using organic solvents. The compound's prenyl groups enhance its lipophilicity and cellular membrane interaction compared to non-prenylated flavonoids.

Historical & Cultural Context

The research sources do not specify any historical or traditional medicinal uses of isolated morusin. The compound is referenced only as a modern phytochemical discovery from mulberry species.

Health Benefits

• Anti-inflammatory effects through NF-κB pathway inhibition and cytokine modulation (preclinical evidence only)
• Antimicrobial activity against tuberculosis strains with MIC values of 6.72-13.45 μg/ml (in vitro studies only)
• Potential anticancer properties via apoptosis induction and cell cycle arrest (cell line studies only)
• Neuroprotective effects shown at 20 mg/kg in mouse seizure models (animal studies only)
• COX/LOX enzyme inhibition for inflammatory pathway modulation (in vitro evidence only)

How It Works

Morusin suppresses inflammatory signaling by blocking IκB kinase (IKK) phosphorylation, thereby preventing nuclear translocation of NF-κB p65 and reducing downstream cytokine production including TNF-α and IL-6. In cancer cell lines, morusin activates the intrinsic apoptotic pathway by upregulating pro-apoptotic proteins Bax and cleaved caspase-3 while downregulating anti-apoptotic Bcl-2, and induces G2/M cell cycle arrest through inhibition of cyclin B1 and CDK1 expression. Its antimicrobial activity against Mycobacterium tuberculosis strains is attributed to disruption of mycobacterial cell wall biosynthesis, with recorded minimum inhibitory concentration (MIC) values of 6.72–13.45 μg/ml in vitro.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on morusin. All available evidence comes from preclinical studies including cell lines (breast cancer MCF-7/MDA-MB-231, PMID: 28599457; prostate DU145/PC3, PMID: 25628938) and animal models, with significant pharmacokinetic barriers preventing human translation.

Clinical Summary

All current evidence for morusin derives from in vitro cell culture studies and rodent animal models, with zero published randomized controlled trials or human pharmacokinetic studies as of 2024. In vitro studies across multiple cancer cell lines, including HeLa, MCF-7, and HepG2, have demonstrated IC50 values in the low micromolar range (typically 5–20 μM) for cytotoxic activity, but these concentrations have not been validated in human plasma. Anti-inflammatory rodent models using lipopolysaccharide (LPS)-induced inflammation showed reduced serum TNF-α and IL-1β following morusin administration, though doses, bioavailability, and metabolic conversion were not standardized across studies. The overall evidence is preliminary and insufficient to support any therapeutic claims in humans.

Nutritional Profile

Morusin is a prenylated flavonoid (molecular formula C₂₀H₁₈O₅, MW 338.35 g/mol) isolated primarily from the root bark of Morus alba (white mulberry). It is not a conventional nutritional compound and contains no meaningful macronutrient, vitamin, mineral, or fiber content as an isolated bioactive. As a pure compound, it is typically studied at microgram-to-milligram dosages (effective preclinical doses range from 5–20 mg/kg in animal models). Its primary bioactive identity lies in its prenylated flavone scaffold, which confers lipophilicity (LogP approximately 3.8), contributing to moderate membrane permeability but poor aqueous solubility (~0.5 μg/mL in water). Oral bioavailability is substantially limited due to rapid hepatic metabolism, low water solubility, and P-glycoprotein efflux; nanoparticle formulations and lipid-based delivery systems have been explored preclinically to improve absorption. No established dietary reference intake or therapeutic dosage exists for human use. Concentrations in Morus alba root bark extracts typically range from 0.02–0.15% dry weight depending on extraction method.

Preparation & Dosage

No clinically studied human dosages exist. Preclinical studies used 0.1-10 mM for in vitro assays, 20 mg/kg in animal seizure models, and 6.72-13.45 μg/ml for antimicrobial effects. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Morusin pairs mechanistically with Quercetin, as both compounds suppress NF-κB signaling but through partially distinct nodes — Morusin inhibits IκB kinase phosphorylation while Quercetin additionally downregulates TNF-α and IL-6 upstream, creating additive anti-inflammatory coverage across the pathway. Piperine (from black pepper, at 20 mg standard doses) is a critically relevant co-ingredient, as it inhibits CYP3A4 and P-glycoprotein efflux — the two primary barriers to Morusin's oral bioavailability — potentially increasing systemic exposure in a manner analogous to its documented 2000% enhancement of curcumin absorption. Berberine presents a complementary anticancer synergy candidate, as preclinical data suggest Berberine activates AMPK-mediated autophagy while Morusin induces caspase-3/9-dependent apoptosis, engaging parallel cell death mechanisms that may reduce resistance development in cancer cell models; additionally, both compounds show activity against Mycobacterium tuberculosis strains, suggesting additive antimicrobial utility at lower individual concentrations.

Safety & Interactions

No human safety data, maximum tolerated dose, or established adverse event profile exists for morusin supplementation due to the complete absence of human clinical trials. In vitro data suggests morusin may inhibit cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9, which could theoretically alter the metabolism of co-administered drugs such as statins, anticoagulants, and immunosuppressants, though this has not been confirmed in vivo. Morusin's potent pro-apoptotic activity in proliferating cells raises theoretical concern for use during pregnancy, and it should be avoided by pregnant or breastfeeding individuals until safety is established. Individuals taking anticoagulants, chemotherapy agents, or immunosuppressive drugs should consult a physician before use due to uncharacterized interaction risks.